Guizhou Yibai Pharmaceutical Co. Ltd.SSE: 600594

Report for Q3 2024

Oct 26, 2024 · Issued by Guizhou Yibai Pharmaceutical Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Oct 26, 2024

On 6ix: 6ix.com/news/report-for-q3-2024-105

Report for Q3 2024

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Guizhou Yibai Pharmaceutical Co. Ltd. on 6ix

Earlier from Guizhou Yibai Pharmaceutical

Announcement on Receipt of "Decision on Administrative Supervision Measures" from Guizhou Securities Regulatory Bureau of China Securities Regulatory CommissionOct 25, 2024
Announcement on Change of Financial Manager of the CompanySep 7, 2024
Announcement on Convening the 2024 Semi-annual Performance BriefingSep 6, 2024
Announcement on Obtaining Drug Registration Certificate for Plerixafor InjectionSep 4, 2024
Semi-annual Report 2024Aug 24, 2024

Later from Guizhou Yibai Pharmaceutical

Announcement on Progress in Repurchasing Shares through Call AuctionNov 2, 2024
Announcement on Convening the Q3 2024 Performance BriefingNov 21, 2024
Announcement on Implementation Result of Repurchasing Shares and Share ChangesNov 29, 2024
Announcement on Postponing Repurchase of Stock-pledged Repurchase TransactionDec 2, 2024
Annual Earnings Preannouncement for 2024Jan 18, 2025

All Guizhou Yibai Pharmaceutical news releases

Follow Guizhou Yibai Pharmaceutical into a list and get an email when it puts out news.

Follow Guizhou Yibai Pharmaceutical